No definition available.
Chromophobe cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)
C3_KIDNEY_CHROMOPHOBE_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
162 |
4. Check minimum number of eventsNone |
162 |
5. Include endpointsNone |
162 |
6. Filter based on genotype QC (FinnGen only) |
162 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
- Name in latin
- Carcinoma in situ labii (oris)
Similar endpoints
↥List of similar endpoints to
Chromophobe cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Chromophobe cell carcinoma of kidney
- Renal cell carcinoma of kidney
- Renal cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of kidney, except renal pelvis
- Malignant neoplasm of urinary organs
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 162 | 57 | 105 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 67.60 | 63.46 | 69.86 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 151
- Matched controls
- 1509
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8317/3-C64.9
ICD-O-3
Renal cell carcinoma, chromophobe type of kidney, NOS
+∞
218.2
151
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
190.8
140
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
2010.4
158.6
127
*
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
+∞
43.9
40
*
KAD01
NOMESCO Finland
Percutaneous endoscopic partial nephrectomy
+∞
40.4
37
*
KAD00
NOMESCO Finland
Partial nephrectomy
+∞
34.7
32
*
JN4AD
NOMESCO Finland
Body CT examination
22.6
29.3
43
26
WX408
NOMESCO Finland
General anesthesy, balanced
7.8
28.1
82
199
JN4CD
NOMESCO Finland
Very extensive body CT
71.0
26.0
29
5
B01AB10
ATC
tinzaparin; parenteral
17.2
25.9
42
33
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
40.0
25.9
32
10
WX302
NOMESCO Finland
Thoracal epidural anesthesy
32.0
25.3
33
13
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
17.7
24.5
39
29
KAC10
NOMESCO Finland
Total nephrectomy with capsule
282.7
24.4
24
*
JN4BD
NOMESCO Finland
Extensive body CT
13.4
21.8
39
38
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.5
19.3
50
93
TPH07
NOMESCO Finland
Cathetrisation of artery
7.9
16.9
41
68
KA1AE
NOMESCO Finland
Kidney ultrasound examination
45.6
16.8
20
5
B01AB05
ATC
enoxaparin; parenteral
4.4
16.1
78
292
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
15.9
15
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
14.8
14
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
14.5
98
477
U75
ICPC
Malignant neoplasm of kidney
+∞
13.7
13
*
130
Kela drug reimbursment
Malignant tumour
+∞
13.7
13
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
13.7
13
*
WX402
NOMESCO Finland
General anaesthesia
4.8
10.8
38
98
N02AX02
ATC
tramadol; systemic, rectal
3.0
9.6
85
454
WZC30
NOMESCO Finland
Teaching
4.8
9.5
33
83
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.5
9
*
N02BE01
ATC
paracetamol; systemic, rectal
5.8
9.4
142
1103
H02AB02
ATC
dexamethasone; systemic
29.4
8.6
11
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
95.0
8.5
9
*
S18
ICPC
Laceration/cut
2.7
7.8
81
455
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
47.4
7.8
9
*
Z51.5
ICD-10 Finland
Palliative care
10.9
7.7
14
14
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.3
7.6
42
159
L01XE04
ATC
[U] sunitinib; oral
+∞
7.3
7
*
KAC00
NOMESCO Finland
Nephrectomy
+∞
7.3
7
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
7.3
7
*
Y77
ICPC
Malignant neoplasm prostate
+∞
7.3
7
*
KA3LT
NOMESCO Finland
Njurlesion coagulation
+∞
7.3
7
*
197
Kela drug reimbursment
Sunitinib
+∞
7.3
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.3
7
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.2
7.3
28
78
SPAT1153
SPAT
Removal of sutures
2.7
7.2
62
309
R4110
NOMESCO Finland
Physiotherapy
2.8
7.1
55
256
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
8.2
7.1
15
20
XKD00
NOMESCO Finland
Uroflowmetry
3.3
7.0
38
140
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
8.9
7.0
14
17
T81.9
ICD-10 Finland
Unspecified complication of procedure
23.7
6.7
9
*
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
23.7
6.7
9
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
13.0
6.7
11
9
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.8
6.6
48
214
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.3
6.5
33
117
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
128
544
7.45
28.84
4.0
3.6
—
—
—
0
0
123
575
5.73
22.68
9.7
5.4
1.2
1.2
mmol/l
1.07
115
519
105
478
4.40
18.82
4.5
2.9
—
—
—
0
0
113
559
4.38
17.63
7.2
3.7
35.5
35.6
g/l
0.05
106
523
117
630
4.09
15.31
10.3
5.8
1.2
1.2
mmol/l
0.83
96
550
82
366
3.51
14.02
4.3
2.7
0.1
0.5
e6/l
4.55
67
269
52
175
3.90
13.62
6.5
6.7
-0.7
1.4
mmol/l
3.61
43
138
150
1020
7.35
13.15
12.0
5.6
81.9
74.9
u/l
1.03
144
941
52
180
3.78
13.02
6.8
6.2
106.0
104.0
mmol/l
2.86
52
174
48
160
3.84
12.66
8.9
5.9
1.0
1.0
mmol/l
0.08
43
148
67
289
3.25
11.70
2.5
2.2
—
—
—
0
0
58
231
3.35
11.53
3.7
2.6
0.5
0.9
e6/l
1.33
35
132
52
211
3.16
9.84
3.7
2.9
1.0
1.7
e6/l
0.34
29
112
26
66
4.50
9.76
3.2
1.4
5.0
2.5
ug/l
0.56
18
54
76
384
2.84
9.65
5.5
2.1
2.4
2.3
mmol/l
1.22
66
327
111
711
2.78
8.47
11.0
6.5
4.1
4.4
e9/l
0.67
96
629
155
1327
4.89
6.11
20.8
13.2
34.9
23.3
mg/l
3.19
145
1015
33
133
2.86
6.10
2.1
2.7
—
—
—
0
0
38
169
2.63
5.81
4.4
2.8
25.9
23.3
%
0.58
31
149
48
241
2.41
5.68
5.1
2.1
2.5
2.4
mmol/l
2.17
43
208
45
222
2.42
5.52
1.7
2.0
30.1
29.6
s
0.29
45
215
8
12
6.95
3.72
1.4
1.2
—
—
—
0
0
123
987
2.02
3.62
4.6
4.3
15.3
11.9
mm/h
1.51
114
901
146
1274
2.48
3.11
25.8
12.0
63.2
77.1
ml/min/173m2
9.83
137
1029
8
17
4.89
2.96
1.5
1.3
—
—
—
0
0
74
532
1.72
2.87
3.1
2.3
82.4
76.7
nmol/l
0.87
68
470
23
112
2.23
2.84
3.7
1.8
49.7
61.8
ml/min/173m2
1.29
15
40
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
42
3.01
2.81
1.3
3.0
0.3
0.3
u/ml
—
5
23
85
645
1.67
2.62
4.4
3.5
0.0
0.0
estimate
0.00
25
88
51
339
1.74
2.57
5.2
3.7
0.0
0.0
estimate
0.49
23
89
83
633
1.64
2.46
5.5
4.8
0.0
0.0
estimate
0.00
24
95
71
527
1.62
2.31
3.6
2.8
274.9
132.4
ug/l
1.10
62
494
26
145
1.94
2.27
1.4
1.9
—
—
—
0
0
155
1442
2.73
2.19
14.6
9.4
26.1
26.3
u/l
0.04
150
1378
81
627
1.58
2.18
4.5
3.5
0.0
0.0
estimate
0.00
25
97
33
204
1.78
2.10
1.6
1.9
—
—
—
0
0
53
378
1.60
1.98
4.3
2.6
396.8
10538.1
umol/l
2.26
45
331
11
49
2.34
1.67
2.1
1.1
2.8
0.0
g/l
0.66
11
44
52
383
1.53
1.66
3.1
2.7
0.7
0.8
ug/l
0.42
39
257
24
146
1.76
1.62
1.5
1.9
—
—
—
0
0
8
32
2.58
1.62
3.6
1.2
78.6
53.6
mg/l
—
8
25
8
32
2.58
1.62
3.6
1.2
23.4
35.2
mg/l
—
8
26
25
158
1.69
1.48
6.7
3.7
6.0
5.8
kpa
0.74
25
151
7
28
2.57
1.47
1.4
1.6
—
—
—
0
0
147
1367
1.81
1.39
5.2
5.0
4.4
4.5
mmol/l
0.40
135
1257
5
17
3.00
1.37
1.0
1.1
—
—
—
0
0
11
54
2.11
1.36
4.5
4.2
4.0
4.0
mmol/l
0.13
11
49
13
70
1.93
1.28
1.8
1.4
—
—
—
0
0
44
330
1.46
1.26
2.8
2.1
3.1
3.0
mg/l
0.03
35
283
6
25
2.45
1.25
1.2
1.3
—
—
—
0
0
6
25
2.45
1.25
1.2
1.3
—
—
—
0
0
5
19
2.68
1.22
1.0
1.4
—
—
—
0
0
145
1357
1.65
1.14
5.1
5.0
1.4
1.4
mmol/l
1.16
132
1236
144
1346
1.63
1.14
5.6
4.9
6.2
6.1
mmol/l
0.22
134
1217
58
467
1.38
1.11
3.8
3.2
2104.4
1384.1
ng/l
0.45
52
399
11
59
1.93
1.10
2.1
1.1
—
—
—
0
0
38
286
1.43
1.07
1.7
1.7
1297.0
1216.7
nmol/l
0.18
24
226
9
47
1.97
1.04
1.6
1.1
37.5
37.7
g/l
—
9
38
44
342
1.39
1.03
1.7
1.6
15.3
20.7
nmol/l
2.32
37
298
141
1318
1.54
1.03
4.5
4.5
1.4
1.3
mmol/l
0.69
128
1191
81
694
1.33
1.02
5.5
4.0
4.6
2.1
ug/l
0.49
74
621
60
492
1.35
1.01
4.8
3.7
—
—
—
0
0
148
1400
1.66
1.01
5.7
5.6
2.6
2.6
mmol/l
0.15
133
1285
134
1242
1.46
1.01
5.6
4.4
1.9
2.0
mu/l
0.09
121
1113
112
1009
1.36
0.99
4.7
3.6
15.1
14.8
pmol/l
0.62
103
900
37
281
1.41
0.99
1.5
1.7
1.4
1.1
mg/l
0.39
27
224
66
553
1.33
0.96
4.2
4.0
22.5
24.6
%
0.47
35
276
17
110
1.61
0.95
2.6
1.2
67.9
66.5
g/l
0.31
17
99
81
701
1.31
0.93
2.3
2.6
—
—
—
0
0
6
30
2.04
0.88
1.5
1.2
—
—
—
0
0
127
1178
1.36
0.84
27.9
14.6
38.6
39.8
%
0.77
87
800
47
382
1.32
0.83
2.1
1.7
1.5
1.3
mmol/l
0.33
38
323
140
1322
1.43
0.80
6.8
6.6
39.8
40.9
mmol/mol
0.77
131
1231
25
184
1.42
0.80
10.2
6.7
—
—
—
0
0
18
124
1.51
0.79
1.2
1.3
—
—
—
0
0
5
26
1.95
0.71
1.8
1.0
—
—
—
0
0
12
77
1.60
0.71
1.6
1.8
—
—
—
0
0
19
139
1.42
0.64
3.2
3.6
323.4
224.0
ng/l
0.32
19
127
0
20
0.00
0.61
0.0
1.2
—
7.6
—
0
13
0
22
0.00
0.60
0.0
4.0
—
—
—
0
0
93
849
1.22
0.59
3.3
3.4
55.8
51.4
u/l
0.19
79
797
10
65
1.57
0.57
2.2
1.6
—
—
—
0
0
6
37
1.64
0.56
2.2
1.5
—
—
—
0
0
25
198
1.31
0.53
1.0
1.3
4.7
14.7
u/ml
—
10
69
9
64
1.43
0.52
1.2
1.9
—
—
—
0
0
6
95
0.62
0.43
2.7
1.8
—
—
—
0
0
5
31
1.63
0.43
1.8
1.5
—
—
—
0
0
5
32
1.58
0.42
6.2
2.5
23.4
25.3
mmol/l
—
5
27
63
569
1.18
0.41
3.8
3.7
127.9
47.6
ng/l
0.56
50
407
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
10
71
1.44
0.40
1.2
2.1
—
—
—
0
0
9
71
1.28
0.37
4.4
3.2
1.3
0.2
e6/l
—
9
71
6
41
1.48
0.36
2.0
1.7
—
—
—
0
0
22
183
1.23
0.34
4.6
5.1
30.4
32.4
%
0.47
14
116
6
46
1.32
0.33
2.3
1.7
—
—
—
0
0
25
212
1.21
0.32
1.1
1.3
25.4
42.4
iu/ml
—
10
68
16
130
1.26
0.30
4.1
2.7
3.9
4.5
kpa
0.86
16
122
63
583
1.13
0.29
2.1
2.0
97.1
92.1
pmol/l
0.29
26
312
5
42
1.20
0.21
1.2
1.2
—
—
—
0
0
5
42
1.20
0.21
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
770.5
—
0
10
0
10
0.00
0.21
0.0
1.1
—
1.0
—
0
5
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
7
89
0.78
0.15
2.7
2.3
1.0
1.3
%
—
7
89
15
166
0.89
0.10
1.5
1.4
—
—
—
0
0
45
454
0.99
0.00
2.1
2.1
174.1
184.6
u/l
0.12
40
417
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
14.0
—
0
8
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
5
50
1.00
0.00
2.4
4.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
5
56
0.89
0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
0.00
1.6
2.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
10.4
—
0
6
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_KIDNEY_CHROMOPHOBE_EXALLC – Chromophobe cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).